Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) plus pembrolizumab (pembro) plus carboplatin (carbo) +/- bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC)